Clinical Features and Outcomes of Pediatric and Adult Patients Hospitalized for Coronavirus Disease 2019: A Comparison Across Age Strata.

SARS-CoV-2 adults children coronavirus coronavirus disease 2019

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 21 03 2024
accepted: 07 08 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 26 8 2024
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19) continues to cause hospitalizations and severe disease in children and adults. This study compared the risk factors, symptoms, and outcomes of children and adults hospitalized for COVID-19 from March 2020 to May 2023 across age strata at 5 US sites participating in the Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence consortium. Eligible patients had an upper respiratory swab that tested positive for severe acute respiratory syndrome coronavirus 2 by nucleic acid amplification. Adjusted odds ratios (aOR) of clinical outcomes were determined for children versus adults, for pediatric age strata compared to adolescents (12-17 years), and for adult age strata compared to young adults (22-49 years). Of 9101 patients in the Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence cohort, 1560 were hospitalized for COVID-19 as the primary reason. Compared to adults (22-105 years, n = 675), children (0-21 years, n = 885) were less commonly vaccinated (14.3% vs 34.5%), more commonly infected with the Omicron variant (49.5% vs 26.1%) and had fewer comorbidities ( Clinical outcomes of COVID-19 differed across pediatric and adult age strata. Adolescents experienced the most severe disease among children, whereas adults 50-64 years experienced the most severe disease among adults.

Sections du résumé

Background UNASSIGNED
Coronavirus disease 2019 (COVID-19) continues to cause hospitalizations and severe disease in children and adults.
Methods UNASSIGNED
This study compared the risk factors, symptoms, and outcomes of children and adults hospitalized for COVID-19 from March 2020 to May 2023 across age strata at 5 US sites participating in the Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence consortium. Eligible patients had an upper respiratory swab that tested positive for severe acute respiratory syndrome coronavirus 2 by nucleic acid amplification. Adjusted odds ratios (aOR) of clinical outcomes were determined for children versus adults, for pediatric age strata compared to adolescents (12-17 years), and for adult age strata compared to young adults (22-49 years).
Results UNASSIGNED
Of 9101 patients in the Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence cohort, 1560 were hospitalized for COVID-19 as the primary reason. Compared to adults (22-105 years, n = 675), children (0-21 years, n = 885) were less commonly vaccinated (14.3% vs 34.5%), more commonly infected with the Omicron variant (49.5% vs 26.1%) and had fewer comorbidities (
Conclusions UNASSIGNED
Clinical outcomes of COVID-19 differed across pediatric and adult age strata. Adolescents experienced the most severe disease among children, whereas adults 50-64 years experienced the most severe disease among adults.

Identifiants

DOI: 10.1093/ofid/ofae443 PMID: 39183814 PMC: PMC11342389
pubmed: 39183814
doi: 10.1093/ofid/ofae443
pii: ofae443
pmc: PMC11342389
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofae443

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. C. A. R.'s institution has received funds to conduct clinical research unrelated to this manuscript from the Centers for Disease Control and Prevention, BioFire Inc, GSK, MedImmune, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. C. Y. C. receives research funding from Abbott Laboratories and Delve Bio on unrelated pathogen detection and discovery projects using metagenomic next-generation sequencing and is a cofounder of and owns equity in Delve Bio. C. Y. C. is also on the scientific advisory board for Biomeme, Biomesense, Flightpath Biosciences, Mammoth Biosciences, and Poppy Health. C. K. is a consultant for Ferring/Rebiotix and a scientific advisor for Seres Therapeutics. A. V. A. is a stockholder of Alzeca Inc. and Sensulin LLC and is on the scientific advisory board of Alezeca Inc.

Auteurs

Grace X Li (GX)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Komal Gopchandani (K)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Noah Brazer (N)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Ashley Tippett (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Chris Choi (C)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Hui-Mien Hsiao (HM)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Miriam Oseguera (M)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Abiodun Foresythe (A)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Sanchita Bhattacharya (S)

Bakar Computational Health Sciences Institute, University of California, San Francisco, CA, USA.

Venice Servellita (V)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Alicia Sotomayor Gonzalez (A)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Jennifer K Spinler (JK)

Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.

Mark D Gonzalez (MD)

Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA, USA.

Dalia Gulick (D)

Georgia Clinical & Translational Science Alliance, Emory University School of Medicine, Atlanta, GA, USA.

Colleen Kraft (C)

Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
ORCID: 0000-0003-1757-8477

Vyjayanti Kasinathan (V)

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Yun F Wayne Wang (YFW)

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Clinical Microbiology Laboratory, Grady Memorial Health Center, Atlanta, GA, USA.

Jennifer Dien Bard (J)

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
ORCID: 0000-0003-0524-9473

Pei Ying Chen (PY)

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Jessica Flores-Vazquez (J)

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Audrey R Odom John (AR)

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Paul J Planet (PJ)

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Sridevi Devaraj (S)

Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.

Ananth V Annapragada (AV)

Department of Radiology, Baylor College of Medicine, Houston, TX, USA.
Department of Radiology, Texas Children's Hospital, Houston, TX, USA.

Ruth Ann Luna (RA)

Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.

Charles Y Chiu (CY)

Department of Laboratory Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.
Department of Medicine, Division of Infectious Diseases, University of California at San Francisco, San Francisco, CA, USA.

Christina A Rostad (CA)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, USA.
ORCID: 0000-0001-8439-0592

Classifications MeSH